Biocon has received an approval for issuance of Redeemable, Non-Convertible Debentures (NCDs) aggregating up to INR equivalent of $250 million on private placement basis. It has also received an approval for issuance of Commercial Paper up to INR equivalent of $275 million on private placement basis. The Board of Directors at its meeting held on November 14, 2022, inter alia, has approved the same.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
